News | April 05, 2021
Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Company to launch product after the expiry of semaglutide patent in India
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Akums invested Rs. 272 crore in capital expenditure during FY25
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
Subscribe To Our Newsletter & Stay Updated
